Enhanced osteogenesis in peri-implant through local hOPG transfection

Abstract

Abstract: PURPOSE : To study the role of local stable expression of OPG in peri-implant in bone regeneration during repair process. METHODS : Sixty-six SD rats were divided into A, B and C group randomly. In group A, adenovirus-hOPG-EGFP was injected around the implant; in group B, adenovirus-EGFP was injected around the implant; in group C, same volume of PBS was injected in the periphery of implant. The animals were sacrificed 1 week, 4 weeks after operation, and the femur bone containing the implant was collected. Micro-CT, H-E staining, toluidine blue staining were used to observe new bone formation. The data was analyzed with SPSS 15.0 software package. RESULTS : A successful vector of reconstructed adenovirus- OPG-GFP as gene therapy was established. In vitro the GFP was successfully expressed in the BMSCs of SD rats. At 4 weeks after implant surgery, osteointegration was observed in all groups. However, % BIC, % bone area, BV/TV, % OI, Tb.N, Tb.Th, Conn.D in the peri-implant area in group A significantly increased compared with the control group (B and C)(P<0.05). Tb.Sp was also significantly less in experimental group (A) than that in control group (B and C). CONCLUSIONS : Local hOPG transfection can be successfully conducted, and the stable expression of protein OPG in peri-implant area can remarkably promote osteogenesis.

Key words: Implant, Adenovirus, Osteoprotegerin, Osteointegration

CLC Number:

R782.1

LI Jia-yang, YIN Guo-zhu, SUN Yue, CHEN Gui-zhen, JI Huan-zhong, LUO En. Enhanced osteogenesis in peri-implant through local hOPG transfection[J]. China Journal of Oral and Maxillofacial Surgery, 2016, 14(1): 1-7.

References

[1] Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis[J]. Biochem Biophys Res Commun,1998,253(2): 395-400.
[2] Gori F, Hofbauer LC, Dunstan CR, et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated [J].Endocrinology,2000,141(12): 4768-4776.
[3] Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption [J].Curr Pharm Des, 2001, 7(8): 613-635.
[4] Pedrosa WF Jr, Okamoto R, Faria PE, et al. Immunohistochemical, tomographic and histological study on onlay bone graft remodeling. Part II: calvarial bone [J].Clin Oral Implants Res,2009, 20(11): 1254-1264.
[5] Baud'huin M, Lamoureux F, Duplomb L, et al. RANKL, RANK, osteoprotegerin: key partners of osteoimunology and vascular diseases [J].Cell Mol Life Sci,2007, 64(18): 2334-2350.
[6] Fekete DM, CePko CL. Replication-competent retroviral vectors eneoding alkaline phosphatase reveal spatial restriction of viral gene expression/transduction in the chick embryo [J].Mol Cell Bio,1993,13(4):2604-2613.
[7] Louis JP. Fibrous carbon implants for the maintenance of bone volume after tooth avulsion: first clinical results [J].Biomaterials,1990,11(9): 525-528.
[8] Fujimoto T, Niimi A, Nakai H, et al. Osseointegrated implants in a patient with osteoporosis: a case report [J]. Int J Oral Maxillofac Implants,1996, 11(4): 539-542.
[9] Ellingsen JE, Johansson CB, Wennerberg A, et al. Improved retention and bone-to-implant contact with fluoride-modified titanium implants [J].Int J Oral Maxillofac Implants, 2004, 19(5): 659-666.
[10] Buser D, Broggini N, Wieland M, et al. Enhanced bone apposition to a chemically modified SLA titanium surface [J].J Dent Res, 2004, 83(7): 529-533.
[11] Coelho PG, Suzuki M. Evaluation of an IBAD thin-film process as an alternative method for surface incorporation of bioceramics on dental implants: a study in dogs[J].J Appl Oral Sci 2005,13(1):87-92.
[12] Kasemo B. Biocompatibility of titanium implants: surface science aspects [J].J Prosthet Dent, 1983,49(6):832-837.
[13] Nanci A, Wuest JD, Peru L, et al. Chemical modification of titanium surfaces for covalent attachment of biological molecules [J].J Biomed Mater Res, 1998, 40(2): 324-335.
[14] Buser D, Schenk RK, Steinemann S, et al. Influence of surface characteristics on bone integration of titanium implants. A histomorphometric study in miniature pigs[J]. J Biomed Mater Res, 1991, 25(7): 889-902.
[15] Ogawa T, Nishimura I. Different bone integration profiles of turned and acidetched implants associated with modulated expression of extracellular matrix genes [J].Int J Oral Maxillofac Implants, 2003,18(2): 200-210.
[16] Takayanagi H, Ogasawara K, Hida S, et al. T-cell mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma [J].Nature, 2000, 408(6812): 600-605.
[17] Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [J].Cell, 1997, 89(2): 309-319.
[18] Wooley PH, Schwarz EM. Aseptic loosening [J].Gene Ther, 2004,11(4): 402-407.
[19] Kofron MD, Laurencin CT. Bone tissue engineering by gene delivery [J].Adv Drug Deliv Rev, 2006,58(4):555-576.